ORIC (ORIC Pharmaceuticals, Inc.) Stock Financials & Earnings

ORICORIC Pharmaceuticals, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$129M

EPS (TTM)-$1.52

Free Cash Flow (TTM)-$112M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$26M
Q2 23	$0	$0	-$25M
Q3 23	$0	$0	-$29M
Q4 23	$0	-$263K	-$31M
Q1 24	$0	-$261K	-$29M
Q2 24	$0	$0	-$36M
Q3 24	$0	$0	-$38M
Q4 24	$0	-$304K	-$40M
Q1 25	$0	$0	-$33M
Q2 25	$0	$0	-$39M
Q3 25	$0	$0	-$37M
Q4 25	$0	-$320K	-$35M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$20M	$6M	—
Q2 23	$19M	$6M	—
Q3 23	$22M	$6M	—
Q4 23	$24M	—	$7M
Q1 24	$22M	$7M	—
Q2 24	$29M	$7M	—
Q3 24	$31M	$7M	—
Q4 24	$32M	—	$7M
Q1 25	$25M	$8M	—
Q2 25	$31M	$9M	—
Q3 25	$29M	$8M	—
Q4 25	$26M	$9M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$59M	$131M	$190M
Q2 23	$104M	$160M	$264M
Q3 23	$26M	$201M	$227M
Q4 23	$23M	$185M	$208M
Q1 24	$56M	$260M	$317M
Q2 24	$50M	$237M	$286M
Q3 24	$44M	$228M	$272M
Q4 24	$59M	$197M	$256M
Q1 25	$49M	$154M	$204M
Q2 25	$76M	$207M	$283M
Q3 25	$50M	$237M	$287M
Q4 25	$46M	$236M	$281M

Shares Outstanding

Revenue Per Employee

Revenue / Employee